Patent · US Active

Anti-CD3 antibodies and uses thereof

US11603405B2 · kind B2 · utility

0Cited by

23References

45Claims

0Family size

Assignee

JANSSEN BIOTECH, INC. · US

Inventors

Francois Gaudet · Princeton, US
Jill Giles-Komar · Downingtown, US
Bradley J. Heidrich · Gilbertsville, US
Chichi Huang · Malvern, US
Colleen Kane · Radnor, US
Ronan McDaid · Eagleville, US
Jennifer Nemeth-Seay · Fort Washington, US

Key dates

Filing date	May 21, 2019
Grant date	Mar 14, 2023
Priority date	—
Expiry date	Jan 3, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.